The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


We have earlier demonstrated that MLAA-22379–387is a novel, acute, monocytic, leukemia-associated antigen epitope in vitro. In this study, the effect and mechanism of MLAA-22379–387on animals have been further examined. We found that tumour weight and volume had significantly decreased in SCID-injected THP-1 mice with MLAA-22379–387treatment for two weeks. MLAA-22379–387induced cytotoxic T lymphocytes (CTL) activity in A549, MCF-7, THP-1, U937 and T2 cells, especially significant CTL activity at effector/target ratio of 50 : 1 in THP-1 cells. The percentage of CD3 + CD8 + T cells had significantly increased, while the percentage of CD4 + CD25 + T cells had significantly decreased in MLAA-22379–387treatment group compared to other groups. Levels of IL-2, IFN-γand IgG had significantly increased, but levels of TGF-βand IL-10 had significantly decreased after MLAA-22379–387vac-cination for two weeks. Thus, we may conclude that MLAA-22379–387treatment effectively improves the immune system, thus indicating tumouricidal capacity in leukaemic mice. These findings highlight the potential application of MLAA-22379–387 as an efficient target for immunotherapy in acute myeloid leukemia.

Keywords

Acute Myeloid Leukemia, Anti-Tumour Activity, Immunotherapy, Mice.
User
Notifications
Font Size